Federal Register / Vol. 62, No. 82 / Tuesday, April 29, 1997 / Notices for any claim that a food, drug, or supplement restores bone strength, reduces or eliminates pain associated with bone ailments, or is superior to any other form of calcium in bioavailability, absorbability, utilization by the body, or treatment or prevention of bone ailments.
In advertising or selling any food drug, or supplement, Part II forbids respondents from misrepresenting the existence, contents, validity, results, conclusions or interpretations of any test or study. In making claims regarding the relationship between calcium and osteoporosis, Part III requires respondents to limit themselves to the health claims authorized by the Food and Drug Administration, as set forth in 58 FR 2665 58 FR (1993 , or to have competent and reliable scientific evidence to support the claims.
Part IV requires respondents to possess competent and reliable scientific evidence to support healthrelated claims for products containing calcium, and to have scientific substantiation for health-related superiority claims for any food, drug, or supplement.
Part V allow respondents to make representations that are specifically permitted by FDA regulations promulgated pursuant to the Nutrition Labeling and Education Act of 1990. Part VI allows respondents to make any claim for a drug that is permitted in labeling for that drug under any tentative or final FDA standard or under any FDA-approved new drug application.
Parts VII through X relate to respondents' obligations to make available to the Commission materials substantiating claims covered by the order; to notify the Commission of changes in Metagenics's corporate structure; to notify the Commission of changes in Mr. Katke's employment or business affiliations; and to provide copies of the orders to certain Metagenics personnel. Part XI provides that the order will terminate after twenty years under certain circumstances. Part XII requires respondents to file periodic compliance reports with the Commission.
The purpose of this analysis is to facilitate public comment on the proposed order, and it is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms. ORI also found that Ms. Huelskamp engaged in scientific misconduct by falsifying patient status data by failing to update the status of treated breast cancer patients and misrepresenting data from previous contacts as the updated status for a study. These data were reported in a grant application to NCI and gave the appearance that some patients' outcomes were more favorable than they actually were.
Ms. Huelskamp cooperated fully with the Johns Hopkins investigation. The investigation report acknowledged her excessive workload, the difficulties associated with recruiting and following up on patients, and a lack of supervisory oversight.
Ms. Huelskamp has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which she has voluntarily agreed, for the three (3) year period beginning April 17, 1997:
(1) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (2) That any institution that submits an application for PHS support for a research project on which Ms. Huelskamp's participation is proposed or which uses her in any capacity on PHS-supported research must concurrently submit a plan for supervision of her duties. The supervisory plan must be designed to ensure the scientific integrity of Ms. Huelskamp's research contribution. The institution must submit a copy of the supervisory plan to ORI.
No scientific publications were required to be corrected as part of this Agreement.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700 Rockville, MD 20852 (301) 443-5330.
